Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response (CONDYVAC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03296397|
Recruitment Status : Unknown
Verified July 2017 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting
First Posted : September 28, 2017
Last Update Posted : February 27, 2018
External genital warts (EGW) are a frequent disease (typical yearly incidence of 100 to 200 new cases per 100.000 person-years, typical prevalence of 1 to 4% of the sexually active population), with a heavy toll on patients' quality of life: low self-esteem and severe impairment of sexual well-being are common consequences. Treatments are painful and take time to achieve cure because of low complete remission (20 to 60%) and high recurrence rates (10 to 40%, 30% on average). Finding new means to reduce these recurrence rates thus seems justified. Infection with Human Papillomavirus (HPV) is responsible for EGW,other warts and some epithelial cancers. Out of two currently available HPV vaccines (Cervarix and Gardasil®), only Gardasil® is " quadrivalent " i.e. contains virus like particles imparting protection versus 4 genotypes of HPV, 2 of them responsible of most cancers and pre cancers of the cervix (HPV 16 and 18), and 2 for 90% of EGW (HPV 6 and 11). A close to 100 % efficacy of the quadrivalent HPV vaccine (QHV) on prevention of EGW in naive patients has been shown, leading to their near disappearance in the vaccinated population of countries with a good vaccine coverage. Beside this preventive efficacy, literature data also show that HPV vaccines have an up-to-100% protective effect versus recurrence of destroyed precancerous lesions of the cervix in non-naive patients with an up-to-40 month's follow-up. Also, there is anecdotal evidence that they could help treat severe wart conditions. QHV is also safe and well tolerated when used in a preventive manner.
Investigator hypothesis is that QHV could have a protective effect on the recurrence of EGW in patients who achieve complete remission.
The primary objective is to evaluate if the HPV vaccine, as compared to placebo, reduces the relapse rate of external genital warts over a 12 month-period after their first injection.
The primary endpoint is the Relapse-free "survival". Relapse will have to be clinically confirmed.
The secondary objectives are : 1. To assess the improvement of the quality of life of the patients 2. To investigate the clinical tolerance to three doses of HPV vaccine. The secondary endpoints are
- Disease relief score as evaluated by patients on a specific questionnaire for Condylomata Acuminata (CECA) and Dermatology Life Quality Index (DLQI) self-administered questionnaires over the treatment and follow-up periods
- The clinical tolerance to HPV vaccine will be evaluated by assessment of the percentage of patients with local and/or systemic reactions during the study
This is a National multicenter Phase III comparative, double blind randomized, two-parallel groups clinical trial evaluating the efficacy of Gardasil vaccine versus placebo in EGW population. Patients (300) recently cured of EGW will be enrolled over a 18 month-period and will be randomized in a 1:1 ratio to receive three intra muscular (IM) vaccinations of either Gardasil vaccine (150 subjects) or placebo (150 subjects) :
- Group 1: Gardasil (at M0) + Gardasil (at M2) + Gardasil (at M6)
- Group 2: Placebo (at M0) + Placebo (at M2) + Placebo (at M6) Subjects meeting all the inclusion criteria and none of the exclusion criteria will be vaccinated by the investigator or designee of the investigational center and will be examined by the investigator or designee 30 minutes post immunization to assess for local and systemic reactions.
All subjects will be followed by the investigators or designee during the study by phone contacts and visits on site. Diary cards will be used after each vaccination to follow the patients.
Number of visits /participant: 9 Schedule of visits : 1 selection visit (V0) , 3 vaccinations scheduled on site at M0, M2 and M6, 3 phone contacts at M1, M3 and M7, 2 clinical follow up visits on site at M9 and M12 + 1 unscheduled visit on site in case of EGW relapse during the study
|Condition or disease||Intervention/treatment||Phase|
|Genital Warts||Biological: Vaccination with Gardasil Biological: Injection of Normal Saline||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place|
|Actual Study Start Date :||November 15, 2017|
|Estimated Primary Completion Date :||March 2020|
|Estimated Study Completion Date :||April 2020|
Active Comparator: HPV Quadrivalent vaccine (QHV)
Biological: Vaccination with Gardasil
Vaccination with Gardasil in patients apparently cured of external genital warts
Placebo Comparator: Placebo
Biological: Injection of Normal Saline
Injection of Normal Saline in patients apparently cured of external genital warts
- Relapse free survival (days from first injection) [ Time Frame: up to 12 months ]
- Improvement of quality of life by Dermatology Life Quality Index (DLQI) validated scale [ Time Frame: at each planned visit/phone contact (1, 2, 3, 6, 7, 9 months), at 12 months (upon end of study visit) or upon premature withdrawal visit ]
- Improvement of quality of life by CECA validated scale [ Time Frame: at each planned visit/phone contact (1, 2, 3, 6, 7, 9 months), at 12 months (upon end of study visit) or upon premature withdrawal visit ]
- Clinical tolerance of QHV (percentage of patients with AE) [ Time Frame: Day 0 ]
- Clinical tolerance of QHV [ Time Frame: Month 2 and Month 6 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03296397
|Contact: Sebastien FOUERE, MD, MSc||(0)1 42 49 99 24 ext +email@example.com|
|Contact: Olivier CHOSIDOW, MD, PhD||(0)1 49 81 25 01 ext +firstname.lastname@example.org|
|Hôpital St Louis||Recruiting|
|Paris, France, 75010|
|Contact: Sebastien FOUERE, MD, MSc (0)1 42 49 99 24 email@example.com|
|GH Cochin - Broca - Hôtel-Dieu,||Not yet recruiting|
|Paris, France, 75679|
|Contact: Odile LAUNAY, PH (0)1 58 41 28 58 ext +33 firstname.lastname@example.org|
|Contact: Laurence MOULAY (0)1 58 41 24 51 ext +33 email@example.com|
|Principal Investigator:||Sebastien FOUERE, MD, MSc||Assistance Publique - Hôpitaux de Paris|